Patents Assigned to ABT Holding Company
-
Patent number: 11918609Abstract: The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.Type: GrantFiled: April 5, 2021Date of Patent: March 5, 2024Assignees: ABT HOLDING COMPANY, KATHOLIEKE UNIVERSITEIT LEUVENInventors: Aernout Luttun, Robert J. Deans
-
Publication number: 20230181651Abstract: The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV-2).Type: ApplicationFiled: April 23, 2021Publication date: June 15, 2023Applicant: ABT Holding CompanyInventors: Anthony E. Ting, Eric D. Jenkins, Alice Valentin-Torres
-
Patent number: 11566834Abstract: An apparatus for cryostorage and manipulation of a plurality of container units includes a cryochamber having a cryo-access port. The cryochamber is electrically cooled at cryogenic temperatures. A unit holder is located inside the cryochamber and is configured to hold a plurality of container units. A user access area is provided for selectively permitting access to a chosen container unit by an authenticated user who has been authenticated by the apparatus. A motive grasper is provided for selectively removing the chosen container unit from the cryochamber through the cryo-access port, and selectively placing the chosen container unit into the user access area.Type: GrantFiled: May 11, 2020Date of Patent: January 31, 2023Assignee: ABT Holding CompanyInventors: Gil Bradford Van Bokkelen, Rakesh Ramachandran, Christopher Robert Bruns, Christopher John Hayes, John A. Corey, Troy M. Coolidge, Bruce E. Frohman, Joseph Gordon, Thomas R. Ruth, Jacob T. Williams, Gregory E. Kramer, Nathan A. Abel, David J. Copeland, Matthew R. Gill, Steven F. Shane
-
Patent number: 11351202Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.Type: GrantFiled: December 20, 2017Date of Patent: June 7, 2022Assignees: ABT HOLDING COMPANY, AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Robert Mays, Robert J. Deans, David C. Hess, James E. Carroll, Cesar V. Borlongan
-
Publication number: 20220118026Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MPACs, in children, for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.Type: ApplicationFiled: December 20, 2021Publication date: April 21, 2022Applicants: ABT Holding Company, AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Robert MAYS, Robert J. DEANS, David C. HESS, James E. CARROLL, Cesar V. BORLONGAN
-
Publication number: 20220110982Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxis and that caused by insufficient blood supply. In some further particulars the invntion relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children, for example, and to the treatment of cortical infants and stroke with MAPCs in adults, for example.Type: ApplicationFiled: December 20, 2021Publication date: April 14, 2022Applicants: ABT Holding Company, AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Robert MAYS, Robert J. Deans, David C. Hess, James E. Carroll, Cesar V. Borlongan
-
Patent number: 11197889Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: GrantFiled: November 6, 2017Date of Patent: December 14, 2021Assignees: ABT Holding Company, Oregon Health & Science UniversityInventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
-
Publication number: 20210346429Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: July 12, 2021Publication date: November 11, 2021Applicants: ABT Holding Company, Oregon Health & Science UniversityInventors: Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Robert DEANS, Wouter VAN'T HOF
-
Publication number: 20210299185Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.Type: ApplicationFiled: June 10, 2021Publication date: September 30, 2021Applicants: ABT Holding Company, AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Robert W. MAYS, Robert J. DEANS, David C. HESS, James E. CARROLL, Cesar V. BORLONGAN
-
Publication number: 20210228626Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: April 9, 2021Publication date: July 29, 2021Applicants: ABT Holding Company, OREGON HEALTH & SCIENCE UNIVERISTYInventors: Robert DEANS, Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Wouter VAN'T HOF
-
Patent number: 11071752Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.Type: GrantFiled: April 16, 2019Date of Patent: July 27, 2021Assignees: ABT Holding Company, Houston Methodist HospitalInventors: Saverio La Francesca, Anthony E. Ting, Robert J. Deans
-
Publication number: 20210205359Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: January 12, 2021Publication date: July 8, 2021Applicants: ABT Holding Company, OREGON HEALTH & SCIENCE UNIVERISTYInventors: Robert Deans, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Wouter Van't Hof
-
Patent number: 10967006Abstract: The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.Type: GrantFiled: February 12, 2016Date of Patent: April 6, 2021Assignees: ABT Holding Company, Katholieke Universiteit LeuvenInventors: Aernout Luttun, Robert J Deans
-
Patent number: 10758570Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1?, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.Type: GrantFiled: April 9, 2018Date of Patent: September 1, 2020Assignee: ABT Holding CompanyInventor: Robert W. Mays
-
Publication number: 20200246390Abstract: Aspects of inventions herein described relate to administration of multipotent adult progenitor cells for treating intracerebral hemorrhage.Type: ApplicationFiled: February 1, 2019Publication date: August 6, 2020Applicant: ABT Holding CompanyInventor: Robert William MAYS
-
Patent number: 10638734Abstract: The present invention relates generally to mammalian multipotent adult stem cells (MASC), and more specifically to methods for obtaining, maintaining and differentiating MASC to cells of multiple tissue types. Uses of MASC in the therapeutic treatment of disease are also provided.Type: GrantFiled: October 19, 2010Date of Patent: May 5, 2020Assignees: ABT Holding Company, Regents of the University of MinnesotaInventors: Leo T. Furcht, Catherine M. Verfaillie, Morayma Reyes
-
Patent number: 10583202Abstract: The invention relates to methods of altering gene expression by homologous recombination in a multipotent adult progenitor cell (MAPC). In particular, methods of producing a recombinant MAPC, of correcting a genetic defect in a mammal, of providing a functional and/or therapeutic protein to a mammal, and of transforming a MAPC are provided. MAPCs containing an erogenous DNA as well as recombinant MAPCs and their differentiated progeny are also provided.Type: GrantFiled: September 19, 2017Date of Patent: March 10, 2020Assignees: ABT Holding Company, Regents of the University of MinnesotaInventors: Catherine M. Verfaillie, Uma Lakshmipathy
-
Patent number: 10272109Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.Type: GrantFiled: January 8, 2018Date of Patent: April 30, 2019Assignee: ABT Holding CompanyInventors: Saverio La Francesca, Anthony E. Ting, Robert J. Deans
-
Patent number: 10226485Abstract: The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.Type: GrantFiled: March 21, 2005Date of Patent: March 12, 2019Assignees: ABT Holding Company, Regents of the University of MinnesotaInventors: Leo T. Furcht, Catherine M. Verfaillie, Morayma Reyes
-
Publication number: 20190048314Abstract: The invention provides methods for treating pathological conditions that can be improved by providing angiogenesis. The invention is generally directed to provide angiogenesis by administering cells that express and/or secrete one or more pro-angiogenic factors. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete one or more pro-angiogenic factors. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of expression and/or secretion of one or more pro-angiogenic factors.Type: ApplicationFiled: March 8, 2018Publication date: February 14, 2019Applicant: ABT Holding CompanyInventors: Juliana Megan Woda, Anthony E. Ting, Nicholas A. Lehman